Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
266 hedge funds and large institutions have $4.57B invested in Intra-Cellular Therapies Inc. in 2022 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 90 reducing their positions, and 19 closing their positions.
142% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 19
35% more call options, than puts
Call options by funds: $33.5M | Put options by funds: $24.9M
10% more funds holding
Funds holding: 241 → 266 (+25)
3% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 90
6% less capital invested
Capital invested by funds: $4.88B → $4.57B (-$307M)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$114M |
| 2 |
Holocene Advisors
New York
|
+$51.3M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$44M |
| 4 |
BlackRock
New York
|
+$32.8M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.8M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BPA
276
Beacon Pointe Advisors
Newport Beach,
California
| – | -$215K | -3,518 | Closed |
|
|
SAM
277
Shikiar Asset Management
New York
| – | -$214K | -3,500 | Closed |
|
|
CG
278
Cutler Group
San Francisco,
California
| – | -$101K | -1,786 | Closed |
|
|
ACM
279
Aquatic Capital Management
Chicago,
Illinois
| – | -$73K | -1,200 | Closed |
|
|
T
280
TCWP
Beachwood,
Ohio
| – | -$2K | -37 | Closed |
|
|
TWC
281
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$1.5K | -24 | Closed |
|
|
EI
282
Ellevest Inc
New York
| – | -$1K | -16 | Closed |
|
|
AF
283
Allworth Financial
Folsom,
California
| – | -$510 | -9 | -82% |
|
284
CI Investments Inc
Toronto,
Ontario, Canada
| – | +$283 | +5 | New |
|
|
CAL
285
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$340 | +6 | New |
|
ITCI Hedge Fund Activity: Q2 2022 in Review
266 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2022, worth a combined $4.57B — down 6.3% from $4.88B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ITCI positions and 19 closed out — a net gain of 27 holders — while 93 added to existing stakes and 90 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $114M. The largest seller was Marshall Wace, exiting entirely with an estimated $154M sold.
- 266 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2022, up from 241 in Q1 2022.
- Funds reported $4.57B of Intra-Cellular Therapies Inc. stock for Q2 2022, down 6.3% quarter-over-quarter.
- 46 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2022 and 19 closed out, a net change of +27 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2022 was AllianceBernstein, an estimated $114M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2022 was Marshall Wace, an estimated $154M sold.
Based on aggregated 13F filings for Q2 2022.